biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs

<< Previous

Bullboard Posts

Next >>

Post by Finallytherockon Jun 15, 2022 11:39am

126 Views

Post# 34758211

chrispi, question

Is the following comment by the company about chiesi positive? LOL

The following statement about milestone and other payments can be found in both the Prothena and Chiesi subsections of Section 11 of the financial report. The passages state, "The Company determined that at this point in time it is remote that any of these payments will be made due to the current state of development of the technology."

<< Previous

Bullboard Posts

Next >>

Canadian artificial intelligence ETFs